https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accounts-payable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accounts-payable-and-accrued-liabilities-fair-value-disclosure https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accounts-payable-related-parties-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accounts-receivable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accrual-at-carrying-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accrual-carrying-value-payments https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accrued-liabilities-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accrued-royalties-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/accumulated-depreciation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/adjustment-of-warrants-granted-for-services https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/amended-reports-10-q https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/buybacks-shares-repurchased https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/capital-expenditures https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cash-and-equivalents https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cash-flow-breakdown https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cash-provided-by-used-in-financing-activities-discontinued-operations https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cash-provided-by-used-in-investing-activities-discontinued-operations https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cash-provided-by-used-in-operating-activities-discontinued-operations https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/common-stock-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/comprehensive-income https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/contractual-obligation-due-in-second-year https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/contractual-obligation-due-in-third-year https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/current-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/current-liabilities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/damages-sought-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-convertible-conversion-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-convertible-threshold-percentage-of-stock-price-trigger https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-interest-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-interest-rate-effective-percentage https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/debt-interest-rate-stated-percentage-rate-range-maximum https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-operating-loss-carryforwards-foreign https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-compensation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/depreciation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/derivative-fair-value-of-derivative-liability-amount-not-offset-against-collateral https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/derivative-liabilities-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/derivative-liability-fair-value-net https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/discontinued-operation-gain-loss-on-disposal-of-discontinued-operation-net-of-tax https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/effective-tax-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/extinguishment-of-debt-amount https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/financing-cash-flow https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/gain-loss-related-to-litigation-settlement https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/gain-or-loss-on-sale-of-stock-in-subsidiary https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/general-and-administrative-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-and-diluted-share https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-loss-from-per-basic-and-diluted-share https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/income-taxes-paid https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-accounts-receivable-and-other-operating-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-interest-payable-net https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-other-current-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-other-deferred-liability https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/insider-transactions-warrants https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-expense-on-debt https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-expense-other https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-paid https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-paid-net https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-payable-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/interest-revenue-expense-net https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/investing-cash-flow https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/investment-income-interest https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/lease-and-rental-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/legal-fees https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/litigation-reserve-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/litigation-reserve-noncurrent https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/litigation-settlement-amount https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/loans-payable-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/machinery-and-equipment-gross https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/minority-interest-in-net-income-loss-other-minority-interests https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-cash-from https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-cash-from-discontinued-operations https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-change-in-cash https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-income https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/net-income-loss-attributable-to-redeemable-noncontrolling-interest https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/noncontrolling-interest-decrease-from-deconsolidation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/notes-payable-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/oci-net-of-tax https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-cash-flow https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-expenses https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-income https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-lease-payments-due https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-commitment https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-current-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-current-liabilities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-income https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/payments-for-legal-settlements https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/payments-to-acquire-machinery-and-equipment https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/proceeds-from-related-party-debt https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/profit-loss https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/property-plant-equipment https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/public-float https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/repayments-of-debt https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/repayments-of-notes-payable https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/research-and-development https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/retained-earnings https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/revenue https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sale-of-stock-percentage-of-ownership-before-transaction https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-10-k https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-10-q https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-10ksb https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-10qsb https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-10sb12g https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-15-12g https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-8-k https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-ct-order https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-def-14c https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-pre-14c https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-sb-2 https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/sec-filings-sc-14f1 https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/settlement-agreement-consideration https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/shareholders-equity https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/shares-authorized https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/shares-issued https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/shares-issued-shares-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/short-term-debt https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-rsu-grants-in-period https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-award-rsu-nonvested-number https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-based-compensation https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-grants-in-period https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/total-assets https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/total-liabilities https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/unrealized-gain-loss-on-derivatives https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/unsecured-debt-current https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/oncovista-innovative-therapies-inc/workers-compensation-liability-current